secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMICUS THERAPEUTICS, INC. (—)
CIK:        0001178879
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001104659-23-105657
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amicus Therapeutics secures $430M financing from Blackstone: $400M term loan + $30M equity
--------------------------------------------------------------------------------

- $400M senior secured term loan at adjusted Term SOFR +6.25% (2.50% floor on SOFR), interest-only until late 2026, matures Oct 2029.
- Proceeds used to refinance existing debt and fund operations; $30M private placement of 2.47M shares at $12.16/share.
- Loan amortization begins Q4 2026 with 12 quarterly payments of $33.33M; prepayment penalties decline over 5 years.
- Equity investors (Blackstone funds) subject to 60-day lock-up; registration statement to be filed by Nov 9, 2023.
- Minimum liquidity covenant of $100M and minimum revenue covenant of $225M (trailing 4 quarters) included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178879/000110465923105657/0001104659-23-105657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178879/000110465923105657/tm2327120d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-105657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer